La AAOC contará con un perfil virtual durante el Congreso con información institucional sobre su misión y actividades, por invitación de ESMO.

Destacados del programa/Highlights

» Further advances of targeted therapies in NSCLC:
– ADAURA: Adjuvant osimertinib in EGFR-mutated NSCLC after resection (LBA1)
– CROWN: Lorlatinib in 1st line ALK-positive advanced NSCLC (LBA2)

» Adjuvant CDK4/6 inhibitors in HR-positive/HER2-negative early breast cancer:
– monarchE: Abemaciclib in high risk early breast cancer (LBA5)
– PALASE: Adjuvant palbociclib in early breast cancer (LBA12)
– Randomized preoperative window of opportunity study with CDK4/6 inhibitor in early breast cancer (161O)

» Blocking PI3K/AKT signalling pathway in mCRPC:
– IPATential150: Ipatasertib plus abiraterone metastatic castration-resistant prostate cancer (LBA4)

» Immunotherapy advances in TNBC:
– IMpassion031: Neoadjuvant atezolizumab plus chemotherapy in early TNBC (LBA11)
– IMpassion130: Final OS analysis of atezolizumab plus nab-paclitaxel in previously untreated advanced TNBC (LBA16)

» Advances in postoperative radiotherapy for NSCLC:
– Lung ART: Post-operative conformal radiotherapy in completely resected NSCLC and mediastinal N2 involvement (LBA3)

» Combination of targeted therapy and immunotherapy:
– LEAP-005: Lenvatinib plus pembrolizumab in previously treated advanced solid tumours (LBA41)
– LEAP-004: Lenvatinib plus pembrolizumab for advanced melanoma that progressed on a PD-1(L1) therapy (LBA44)

ACCESO ONLINE:
www.esmo.org/meetings/esmo-virtual-congress-2020

EN LAS REDES:
Twitter
Facebook
LinkedIn
Instagram
YouTube